EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies

Lingzhi Wang, Qing Li, Xiaojian Zhu

Cancer Treatment and Research Communications · 2026 · 49 · 101425

DOI: 10.1016/j.ctarc.2026.101425 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Lingzhi Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Die Arbeit nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for large B-cell lymphoma (LBCL), particularly in the relapsed or refractory. However, relapse after CAR-T cell therapy remains a major barrier to durable remission and long-term survival because post-CAR-T relapse is biologically and clinically heterogeneous and lacks standardized management strategies. In this narrative review, we provide a clinically oriented synthesis of the current evidence on relapse or progression after CAR-T cell therapy in LBCL, focusing on relapse patterns, underlying biological mechanisms, risk factors, and evolving salvage strategies. Evidence from other B-cell lymphoma subtypes is included selectively when it provides relevant biological or clinical context, but it is not considered directly interchangeable with findings from LBCL. We delineate the heterogeneity of post-CAR-T cell recurrence across lymphoma subtypes, emphasizing differences in the timing, patterns of progression, and antigen expression. We then discuss the principal determinants of treatment failure, including patient-related factors, tumor-intrinsic features, impaired CAR-T cell expansion and persistence, an immunosuppressive tumor microenvironment, and treatment-induced selective pressures. We also summarize current salvage strategies, including bispecific antibodies, CAR-T cell reinfusion, allogeneic hematopoietic stem cell transplantation, and investigational approaches under clinical evaluation. Among these, bispecific antibodies have demonstrated promising efficacy in real-world settings and are increasingly being incorporated into post-CAR-T cell treatment algorithms. Overall, post-CAR-T cell relapse is a multifactorial process with important clinical implications. Integrating mechanistic insights with emerging therapeutic advances may enable more individualized salvage strategies. Future research should focus on improved risk stratification, biomarker-guided surveillance, optimization of treatment sequencing, and the development of next-generation cellular and combinatorial immunotherapies to improve long-term outcomes.

Schlagwörter

Stichwörter der Autor:innen

CAR-TCell therapyLarge B-cell lymphomaProgressionRelapseSalvage therapy

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Hematology, Wuhan First Hospital, Wuhan, Hubei, China.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: zhuxiaojian@hust.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, L., Li, Q., & Zhu, X. (2026). Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies. Cancer Treatment and Research Communications, 49, 101425. https://doi.org/10.1016/j.ctarc.2026.101425

Vancouver

Wang L, Li Q, Zhu X. Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies. Cancer Treatment and Research Communications. 2026;49:101425. doi:10.1016/j.ctarc.2026.101425

BibTeX
@article{Wang2026,
  author = {Wang, Lingzhi and Li, Qing and Zhu, Xiaojian},
  title = {Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {49},
  pages = {101425},
  doi = {10.1016/j.ctarc.2026.101425}
}
Kostenlos starten →